- 01A monitoring marker with two opposite blind spots
CA 19-9 follows a cancer that is already diagnosed, most often pancreatic. As a standalone test it fails in both directions: about 1 in 10 people are Lewis-negative and make almost none of it even with advanced cancer, while a blocked bile duct or an inflamed pancreas can push it into the thousands with no cancer at all.
CA 19-9 (carbohydrate antigen 19-9, a sugar-protein shed into the blood by cells lining the pancreas and bile ducts) is a monitoring blood test for a cancer that has already been diagnosed, most often pancreatic cancer. It is not a screening test and not a diagnosis: a high number is more often caused by a blocked bile duct or an inflamed pancreas than by cancer, and a normal number can miss disease entirely, because about 5 to 10% of people make almost none of it.
What is CA 19-9?
CA 19-9 stands for carbohydrate antigen 19-9, a sugar molecule attached to proteins on the surface of cells lining the pancreas and bile ducts. Some of it ends up in the blood, where a lab can measure it in units per milliliter (U/mL). It was first identified using an antibody raised against colorectal cancer cells, which is why it became a tumor marker.
Both cancer cells and healthy cells make CA 19-9, which is why the number climbs in plenty of situations that have nothing to do with cancer. Its steady job is narrower, following a pancreatic cancer that has already been diagnosed. For the wider picture of why a tumor marker is not a cancer test, see tumor markers explained.
Most tumor markers were built to watch a cancer that is already diagnosed, not to find one in a healthy person.
What is a normal CA 19-9 level?
There is no single universal normal. Most labs flag CA 19-9 as high above about 37 U/mL, but the exact cutoff is lab-dependent, and the number means different things depending on why the test was ordered. 23 The table below shows how labs typically read the ranges, and what each range does and does not tell you.
| CA 19-9 level | How labs usually read it | What it does and doesn't tell you |
|---|---|---|
| At or below about 37 U/mL | Within the common reference range | Reassuring only if you make CA 19-9 normally; Lewis-negative people can sit here even with advanced cancer. 34 |
| Mildly to moderately high (about 37 to a few hundred U/mL) | Flagged high | Most often a benign cause like a blocked bile duct, gallstones, or pancreatitis, not cancer. 5 |
| Very high (hundreds to thousands of U/mL) | Flagged high | More concerning in someone with a known or suspected pancreatic cancer, though a blocked bile duct alone can also reach these levels. 5 |
Where an example CA 19-9 might fallU/mL
What does a high CA 19-9 mean?
A high CA 19-9 is not a cancer diagnosis. In a person with no known cancer, most elevated results come from benign conditions of the bile ducts, pancreas, or liver. Even in a person with a diagnosed pancreatic cancer, one high value is read against imaging and the trend of earlier results, not on its own. A clinician reads the number for two things: whether it is changing over time, and whether it fits the imaging and symptoms.
What causes a high CA 19-9 besides cancer?
| Cause | Cancer or benign? | What to know |
|---|---|---|
| Pancreatic cancer | Cancer | The main reason CA 19-9 is measured; used to follow a diagnosed cancer, where the trend over time matters more than one value. 2 |
| Bile-duct, gallbladder, stomach, or colon cancer | Cancer | Can also raise it, so a high value cannot point to one organ. |
| Blocked bile duct / obstructive jaundice (backed-up bile that yellows the skin) | Benign | A very common false-high; in one series 61% of people with benign obstructive jaundice were above the 37 U/mL cutoff. 5 |
| Pancreatitis or cholangitis (inflamed pancreas or bile duct) | Benign | Inflammation alone can push it up. |
| Cirrhosis (long-term liver scarring) and other liver disease | Benign | Can raise it modestly. |
| Lewis-negative status (about 5 to 10% of people) | Neither | These people make almost no CA 19-9, so their level can stay low even with advanced pancreatic cancer. 34 |
CA 19-9 and pancreatic cancer: why the trend matters
CA 19-9's established role is following a pancreatic cancer that has already been diagnosed. During and after treatment, it is often drawn alongside imaging: a value that falls after surgery or chemotherapy points toward treatment working, while a steady climb can be the first hint the cancer has returned, sometimes before symptoms appear. 2 The single number matters less than its direction over time.
Why CA 19-9 is not a screening test
CA 19-9 is not recommended for screening people who feel well, because it fails in both directions. It misses cancer in the people who cannot make it, and it flags cancer that is not there when the bile ducts are blocked or inflamed. Used on a healthy population, it would generate far more false alarms and false reassurances than useful answers. 12
Because tumor markers can also be elevated in noncancerous conditions, and because they are not elevated in everyone who has a particular cancer, the use of tumor markers alone is usually not enough to diagnose cancer.National Cancer Institute, Tumor Markers in Common Use
How the CA 19-9 test is done, and how often
- It is a simple blood draw. No fasting or special preparation is needed for most labs. 3
- It is ordered on its own, not as part of a routine wellness panel, usually when a pancreatic or bile-duct cancer is suspected or being followed. 2
- When it is used to monitor a diagnosed cancer, it is often drawn alongside imaging every few months during and after treatment; the clinician sets the interval. 2
- It is not recommended as a self-requested cancer screen. 1 Whether insurance covers it typically depends on your situation and plan, so check with your insurer.
In gastrointestinal cancers, CA 19-9 is sometimes tracked alongside CEA, another marker used to follow disease after treatment. Neither one screens for or diagnoses cancer on its own; both make sense only next to imaging, symptoms, and a clinician's read.
Link · National Cancer InstituteTumor markers in common useThe NCI's plain-language list of tumor markers, what each is used for, and why they are not cancer screening tests.cancer.gov
Citations
- National Cancer Institute, Tumor Markers in Common Use, 2024
- Locker GY, et al. ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer. J Clin Oncol. 2006;24(33):5313-5327
- Mayo Clinic Laboratories. CA 19-9 (Carbohydrate Antigen 19-9), Serum, test overview
- Tempero MA, et al. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987;47(20):5501-5503
- Marrelli D, et al. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg. 2009;198(3):333-339
Educational context only, not medical advice or a diagnosis. Always discuss your results with a clinician.